Compounds > clopidogrel

clopidogrel and mephenytoin

clopidogrel has been researched along with mephenytoin in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Farid, NA; Hagihara, K; Ikeda, T; Ishizuka, T; Kazui, M; Kurihara, A; Nishiya, Y; Okazaki, O1
El Rouby, N; Goldstein, JA; Johnson, JA; Langaee, TY; Markowitz, JS; Wang, X; Zhu, HJ1
Calamia, JC; Chaudhry, AS; Fohner, A; Isoherranen, N; McDonald, M; Prasad, B; Rettie, AE; Schuetz, EG; Shirasaka, Y; Thornton, TA; Thummel, KE; Unadkat, JD; Wong, T1

Reviews

1 review(s) available for clopidogrel and mephenytoin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

4 other study(ies) available for clopidogrel and mephenytoin

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:1

    Topics: Antibodies; Aryl Hydrocarbon Hydroxylases; Biocatalysis; Biotransformation; Cell Line; Cell Line, Tumor; Clopidogrel; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Glutathione; Humans; Ketoconazole; Kinetics; Mephenytoin; Microsomes; Microsomes, Liver; NADP; Omeprazole; Oxidation-Reduction; Oxidoreductases, N-Demethylating; Platelet Aggregation Inhibitors; Sulfaphenazole; Theophylline; Ticlopidine

2010
The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping.
    Pharmacogenetics and genomics, 2014, Volume: 24, Issue:8

    Topics: Alleles; Aryl Hydrocarbon Hydroxylases; Catalysis; Chromatography, Liquid; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Kinetics; Mephenytoin; Omeprazole; Pharmacogenetics; Polymorphism, Single Nucleotide; Sequence Analysis, DNA; Tandem Mass Spectrometry; Ticlopidine

2014
Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content.
    The pharmacogenomics journal, 2016, Volume: 16, Issue:4

    Topics: Activation, Metabolic; Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Female; Gene Expression Regulation, Enzymologic; Gene Frequency; Genotype; Humans; Hydroxylation; Infant; Infant, Newborn; Kinetics; Linear Models; Liver; Male; Mephenytoin; Microsomes, Liver; Middle Aged; Multivariate Analysis; Oxidation-Reduction; Pharmacogenomic Variants; Phenotype; Substrate Specificity; Ticlopidine; Young Adult

2016